Metastatic Prostate Cancer with Charles Ryan, MD and William K. Oh, MD: Case 1
Metastatic Prostate Cancer with Charles Ryan, MD and William K. Oh, MD
CASE: Metastatic Prostate Cancer (Part 1)
Stanley S is an 83-year-old Caucasian male whose past medical history includes diagnosis of adenocarcinoma of the prostate in 2012 with no evidence of metastasis. At the time, he was started on bicalutamide and his serum PSA levels subsequently decreased to 1.2 ng/ml.
During his most recent follow-up exam, the patient complained of intermittent back pain and increasing fatigue.
- His serum PSA level is 56.9 ng/ml and his alkaline phosphatase is 258 U/L
- CT scan shows enlarged lumbar bone metastasis with associated soft tissue component, as well as symptomatic nodes with lumbar bone metastases
- Biopsies of the prostate and transrectal ultrasound reveal the prostate is 42 grams
- Ten of 14 cores are positive for prostate cancer for a Gleason score of 8 (4 + 4)
- His ECOG performance status score is a 2
Apalutamide Outperforms Enzalutamide in mCSPC Survival
November 8th 2024In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
